The prevalence of Alzheimer’s Disease is rising, in part due to increase in the medium age of residents in developed countries. The aim of the study has been to determine whether resveratrol (RSV) can be effective in the prevention or treatment of Alzheimer’s Disease, providing its antioxidant, anti-inflammatory, and SIRT1-activating properties.
A systematic review of some experimental and clinical studies has been made. The eligibility criteria have comprised: maximum 10 years passed from the study publication, geographical diversity of the studies performed, and – as much as possible – pertaining of the reviewed study results both to animal models of AD, and to humans.
After the final assessment of the eligibility criteria, 96 research studies have been included in the review. Overall results suggest that RSV can be effectively used in the prevention of AD, especially in reference to its familial forms with an early onset. At the same time, efficacy of RSV in the treatment of AD needs further studies, aimed at: improving its transport through the blood-brain barrier (BBB), performing prospective clinical in vivo trials on large groups of patients, and determining the optimal RSV dosage.
Providing RSV mechanisms of action, inhibitory in reference to many pathomechanisms of AD, it seems very likely that RSV could be effective in AD prevention. The main limitations referring to such presumption include: limited permeability of BBB to RSV, and scarcity of clinical studies on RSV pertaining to large groups of humans.

Copyright © 2020 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Author